Pallas Capital Advisors LLC Purchases 2,773 Shares of Medpace Holdings, Inc. $MEDP

Pallas Capital Advisors LLC raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 154.1% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 4,573 shares of the company’s stock after purchasing an additional 2,773 shares during the quarter. Pallas Capital Advisors LLC’s holdings in Medpace were worth $2,351,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Wasatch Advisors LP lifted its stake in shares of Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares during the last quarter. Mawer Investment Management Ltd. increased its stake in Medpace by 17.4% in the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after purchasing an additional 121,213 shares during the period. AQR Capital Management LLC lifted its position in shares of Medpace by 15.1% during the second quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after purchasing an additional 81,637 shares during the last quarter. Baillie Gifford & Co. boosted its stake in shares of Medpace by 12.0% during the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after purchasing an additional 62,503 shares during the period. Finally, Epoch Investment Partners Inc. boosted its stake in shares of Medpace by 11.4% during the second quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock valued at $139,740,000 after purchasing an additional 45,435 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Performance

NASDAQ:MEDP opened at $428.03 on Tuesday. The firm has a 50-day simple moving average of $565.10 and a 200-day simple moving average of $539.07. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92. The firm has a market cap of $12.15 billion, a P/E ratio of 27.98, a P/E/G ratio of 2.05 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. Medpace’s revenue was up 32.0% compared to the same quarter last year. During the same period last year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research note on Friday. TD Cowen reaffirmed a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Mizuho set a $582.00 price target on shares of Medpace in a research note on Wednesday, February 11th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Finally, Barclays dropped their price objective on Medpace from $525.00 to $500.00 and set an “underweight” rating on the stock in a research note on Wednesday, February 11th. Four research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $487.36.

Insider Activity

In other news, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the transaction, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. The trade was a 7.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Kevin M. Brady sold 3,000 shares of the company’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $590.35, for a total value of $1,771,050.00. Following the sale, the chief financial officer owned 6,000 shares of the company’s stock, valued at $3,542,100. This trade represents a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 257,295 shares of company stock worth $155,300,319. 20.30% of the stock is currently owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.